お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
市場調査レポート
商品コード
966743

後天性血栓性血小板減少性紫斑病:疫学考察 (~2030年)

Acquired Thrombotic Thrombocytopenic Purpura - Epidemiology Insight - 2030

出版日: 受注生産 | 発行: DelveInsight Business Research LLP | ページ情報: 英文 100 Pages | 納期: 約10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.84円
後天性血栓性血小板減少性紫斑病:疫学考察 (~2030年)
出版日: 受注生産
発行: DelveInsight Business Research LLP
ページ情報: 英文 100 Pages
納期: 約10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、米国、欧州5ヶ国(ドイツ、スペイン、イタリア、フランス、英国)、および日本の7つの主要市場における後天性血栓性血小板減少性紫斑病 (後天性TTP) 市場について詳細に説明し、SWOT分析、疾患のリスクと負担、アンメットニーズ、有病率の高い症例、診断数・治療数などに関する情報を提供しています。

目次

第1章 重要考察

第2章 エグゼクティブサマリー

第3章 後天性血栓性血小板減少性紫斑病:疾患の背景と概要

  • イントロダクション
  • 兆候と症状
  • 病態生理学
  • 危険因子
  • 診断

第4章 ペイシェントジャーニー

第5章 疫学と患者人口

  • 疫学の主な調査結果
  • 前提条件と理論的根拠:主要7ヶ国
  • 疫学シナリオ:主要7ヶ国
    • 主要7ヶ国における後天性血栓性血小板減少性紫斑病の疫学シナリオ
  • 米国の疫学
    • 米国における後天性血栓性血小板減少性紫斑病の疫学シナリオ
  • 欧州5ヶ国の疫学:国別
    • ドイツの疫学
    • フランスの疫学
    • イタリアの疫学
    • スペインの疫学
    • 英国の疫学
  • 日本の疫学
    • 日本における後天性血栓性血小板減少性紫斑病の疫学シナリオ

第6章 治療アルゴリズム、現在の治療、および医療行為

  • 治療と管理
  • 治療アルゴリズム

第7章 KOL の見解

第8章 アンメットニーズ

第9章 付録

  • 参考文献
  • レポートの調査手法

第10章 DelveInsightのサービス内容

第11章 免責事項

第12章 DelveInsightについて

図表

List of Tables

  • Table 1: Acquired Thrombotic Thrombocytopenic Purpura Epidemiology in 7MM (2017-2030)
  • Table 2: Acquired Thrombotic Thrombocytopenic Purpura Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Table 3: Acquired Thrombotic Thrombocytopenic Purpura Epidemiology in the United States (2017-2030)
  • Table 4: Acquired Thrombotic Thrombocytopenic Purpura Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5: Acquired Thrombotic Thrombocytopenic Purpura Epidemiology in Germany (2017-2030)
  • Table 6: Acquired Thrombotic Thrombocytopenic Purpura Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7: Acquired Thrombotic Thrombocytopenic Purpura Epidemiology in France (2017-2030)
  • Table 8: Acquired Thrombotic Thrombocytopenic Purpura Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9: Acquired Thrombotic Thrombocytopenic Purpura Epidemiology in Italy (2017-2030)
  • Table 10: Acquired Thrombotic Thrombocytopenic Purpura Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11: Acquired Thrombotic Thrombocytopenic Purpura Epidemiology in Spain (2017-2030)
  • Table 12: Acquired Thrombotic Thrombocytopenic Purpura Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13: Acquired Thrombotic Thrombocytopenic Purpura Epidemiology in the United Kingdom (2017-2030)
  • Table 14: Acquired Thrombotic Thrombocytopenic Purpura Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Table 15: Acquired Thrombotic Thrombocytopenic Purpura Epidemiology in Japan (2017-2030)
  • Table 16: Acquired Thrombotic Thrombocytopenic Purpura Diagnosed and Treatable Cases in Japan (2017-2030)

List of Figures

  • Figure 1: Acquired Thrombotic Thrombocytopenic Purpura Epidemiology in 7MM (2017-2030)
  • Figure 2: Acquired Thrombotic Thrombocytopenic Purpura Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Figure 3: Acquired Thrombotic Thrombocytopenic Purpura Epidemiology in the United States (2017-2030)
  • Figure 4: Acquired Thrombotic Thrombocytopenic Purpura Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5: Acquired Thrombotic Thrombocytopenic Purpura Epidemiology in Germany (2017-2030)
  • Figure 6: Acquired Thrombotic Thrombocytopenic Purpura Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7: Acquired Thrombotic Thrombocytopenic Purpura Epidemiology in France (2017-2030)
  • Figure 8: Acquired Thrombotic Thrombocytopenic Purpura Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9: Acquired Thrombotic Thrombocytopenic Purpura Epidemiology in Italy (2017-2030)
  • Figure 10: Acquired Thrombotic Thrombocytopenic Purpura Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11: Acquired Thrombotic Thrombocytopenic Purpura Epidemiology in Spain (2017-2030)
  • Figure 12: Acquired Thrombotic Thrombocytopenic Purpura Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13: Acquired Thrombotic Thrombocytopenic Purpura Epidemiology in the United Kingdom (2017-2030)
  • Figure 14: Acquired Thrombotic Thrombocytopenic Purpura Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Figure 15: Acquired Thrombotic Thrombocytopenic Purpura Epidemiology in Japan (2017-2030)
  • Figure 16: Acquired Thrombotic Thrombocytopenic Purpura Diagnosed and Treatable Cases in Japan (2017-2030)

The table of contents is not exhaustive; will be provided in the final report

目次
Product Code: DIEI1018

DelveInsight's 'Acquired Thrombotic Thrombocytopenic Purpura - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Acquired Thrombotic Thrombocytopenic Purpura epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Acquired Thrombotic Thrombocytopenic Purpura Understanding

The DelveInsight Acquired Thrombotic Thrombocytopenic Purpura epidemiology report gives a thorough understanding of the Acquired Thrombotic Thrombocytopenic Purpura by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Acquired Thrombotic Thrombocytopenic Purpura in the US, Europe, and Japan. The report covers the detailed information of the Acquired Thrombotic Thrombocytopenic Purpura epidemiology scenario in seven major countries (US, EU5, and Japan).

Acquired Thrombotic Thrombocytopenic Purpura Epidemiology Perspective by DelveInsight

The Acquired Thrombotic Thrombocytopenic Purpura epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Acquired Thrombotic Thrombocytopenic Purpura epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Acquired Thrombotic Thrombocytopenic Purpura epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Acquired Thrombotic Thrombocytopenic Purpura Detailed Epidemiology Segmentation

The Acquired Thrombotic Thrombocytopenic Purpura epidemiology covered in the report provides historical as well as forecasted Acquired Thrombotic Thrombocytopenic Purpura epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Acquired Thrombotic Thrombocytopenic Purpura report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report:

  • The Acquired Thrombotic Thrombocytopenic Purpura report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Acquired Thrombotic Thrombocytopenic Purpura Epidemiology Report and Model provide an overview of the risk factors and global trends of Acquired Thrombotic Thrombocytopenic Purpura in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Acquired Thrombotic Thrombocytopenic Purpura in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Acquired Thrombotic Thrombocytopenic Purpura
  • The report provides the segmentation of the Acquired Thrombotic Thrombocytopenic Purpura epidemiology

Report Highlights:

  • 11-Year Forecast of Acquired Thrombotic Thrombocytopenic Purpura epidemiology
  • 7MM Coverage
  • Total Cases of Acquired Thrombotic Thrombocytopenic Purpura
  • Total Cases of Acquired Thrombotic Thrombocytopenic Purpura according to segmentation
  • Diagnosed cases of Acquired Thrombotic Thrombocytopenic Purpura

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Acquired Thrombotic Thrombocytopenic Purpura?
  • What are the key findings pertaining to the Acquired Thrombotic Thrombocytopenic Purpura epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Acquired Thrombotic Thrombocytopenic Purpura across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Acquired Thrombotic Thrombocytopenic Purpura?
  • What are the currently available treatments of Acquired Thrombotic Thrombocytopenic Purpura?

Reasons to buy:

  • The Acquired Thrombotic Thrombocytopenic Purpura Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Acquired Thrombotic Thrombocytopenic Purpura market
  • Quantify patient populations in the global Acquired Thrombotic Thrombocytopenic Purpura market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Acquired Thrombotic Thrombocytopenic Purpura therapeutics in each of the markets covered
  • Understand the magnitude of Acquired Thrombotic Thrombocytopenic Purpura population by its epidemiology
  • The Acquired Thrombotic Thrombocytopenic Purpura Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Executive Summary of Acquired Thrombotic Thrombocytopenic Purpura

3. Acquired Thrombotic Thrombocytopenic Purpura : Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Sign and Symptoms
  • 3.3. Pathophysiology
  • 3.4. Risk Factors
  • 3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

  • 5.1. Epidemiology Key Findings
  • 5.2. Assumptions and Rationale: 7MM
  • 5.3. Epidemiology Scenario: 7MM
    • 5.3.1. Acquired Thrombotic Thrombocytopenic Purpura Epidemiology Scenario in the 7MM (2017- 2030)
  • 5.4. United States Epidemiology
    • 5.4.1. Acquired Thrombotic Thrombocytopenic Purpura Epidemiology Scenario in the United States (2017- 2030)
  • 5.5. EU-5 Country-wise Epidemiology
    • 5.5.1. Germany Epidemiology
      • 5.5.1.1. Acquired Thrombotic Thrombocytopenic Purpura Epidemiology Scenario in Germany (2017- 2030)
    • 5.5.2. France Epidemiology
      • 5.5.2.1. Acquired Thrombotic Thrombocytopenic Purpura Epidemiology Scenario in France (2017- 2030)
    • 5.5.3. Italy Epidemiology
      • 5.5.3.1. Acquired Thrombotic Thrombocytopenic Purpura Epidemiology Scenario in Italy (2017- 2030)
    • 5.5.4. Spain Epidemiology
      • 5.5.4.1. Acquired Thrombotic Thrombocytopenic Purpura Epidemiology Scenario in Spain (2017- 2030)
    • 5.5.5. United Kingdom Epidemiology
      • 5.5.5.1. Acquired Thrombotic Thrombocytopenic Purpura Epidemiology Scenario in the United Kingdom (2017-2030)
  • 5.6. Japan Epidemiology
    • 5.6.1. Acquired Thrombotic Thrombocytopenic Purpura Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

  • 6.1. Acquired Thrombotic Thrombocytopenic Purpura Treatment and Management
  • 6.2. Acquired Thrombotic Thrombocytopenic Purpura Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

  • 9.1. Bibliography
  • 9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

The table of contents is not exhaustive; will be provided in the final report

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.